Twenty years of pharmacology

Journal of Head Trauma Rehabilitation

Volumn 20, Issue 1, 2005, Pages 51-61

  Glenn, Mel B ^a,b   Wroblewski, Bruno ^c  

^a and Red Sox Foundation and Massachusetts General Hospital Home Base Program   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NeighborCare   (United States)

Author keywords

Anticonvulsants; Antidepressants; Antipsychotic drugs; Antispasticity drugs; Pharmacology; Traumatic brain injury

Indexed keywords

AMANTADINE; AMPHETAMINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATOMOXETINE; BROMOCRIPTINE; CARBAMAZEPINE; CENTRAL STIMULANT AGENT; CHOLINESTERASE INHIBITOR; CITALOPRAM; DEXAMPHETAMINE; DONEPEZIL; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; GALANTAMINE; METHYLPHENIDATE; MODAFINIL; NEUROLEPTIC AGENT; PAROXETINE; PEMOLINE MAGNESIUM; RIVASTIGMINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

AGITATION; ANOREXIA; APPETITE DISORDER; ATTENTION DEFICIT DISORDER; BRAIN INFARCTION; COGNITIVE DEFECT; COST EFFECTIVENESS ANALYSIS; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DYSPNEA; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART MUSCLE ISCHEMIA; HEART PALPITATION; HISTORY OF MEDICINE; HUMAN; HYPERTENSION; INSOMNIA; LIVER TOXICITY; MENTAL DISEASE; PATIENT COMPLIANCE; PHARMACOLOGY; REVIEW; SEXUAL DYSFUNCTION; SHOCK; SIDE EFFECT; SLEEP DISORDER; STATISTICAL SIGNIFICANCE; SUSTAINED RELEASE PREPARATION; THORAX PAIN; TRANQUILIZING ACTIVITY; TRAUMATIC BRAIN INJURY; TREMOR; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 13844273218     PISSN: 08859701     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001199-200501000-00006     Document Type: Review

References (68)

1. Glenn MB, Wroblewski B. Anticonvulsants for prophylaxix of post-traumatic seizures. J Head Trauma Rehabil. 1986;1(1):73.
2. Temkin NR, Dikmen SS, Wilensky AJ, Keihm J, Chabal S, Winn R. A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. N Engl J Med. 1990;323:497-502.
3. Glenn MB. Anticonvulsants reconsidered. J Head Trauma Rehabil. 1991;6(3):85-88.
4. Temkin NR, Dikmen SS, Anderson GD, et al. Valproate therapy for prevention of posttraumatic seizures: a randomized trial. J Neurosurg. 1999;91:593-600.
5. Hoch DB, Daly L. Anticonvulsants. J Head Trauma Rehabil. 2003;18(4):383-386.
6. Martin R, Kuzniecky R, Ho S, et al. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology. 1999;52:321-327.
7. Bergin AM, Connolly M. New antiepileptic drug therapies. Neurol Clin N Am. 2002;20:1163-1182.
8. Agosti RM, Katz DI. New antiepileptic drugs. J Head Trauma Rehabil. 1996;11(4):100-103.
9. Elovic E. Use of provigil for underarousal following TBI. J Head Trauma Rehabil. 2000;15(4):1068-1071.
10. Anorexigenic agents and respiratory and cerebral stimulants. In: McEvoy K, ed. AHFS Drug Information. Bethesda, Md: American Society of Health-System Pharmacists; 2003:2313-2343.
11. Miscellaneous central nervous system agents. In: McEvoy K, ed. AHFS Drug Information. Bethesda, Md: American Society of Health-System Pharmacists; 2003:2414-2458.
12. Atomoxetine (Strattera) for ADHD. Med Lett. 2003;45(1149):11-12.
13. Wernicke JF, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry. 2002;63(suppl 12):50-55.
14. Cowell LC, Cohen RF. Amantadine: a potential adjuvant therapy following traumatic brain injury. J Head Trauma Rehabil. 1995;10(6):91-94.
15. Meythaler JM, Brunner RC, Johnson A, Novack T. Amantadine to improve neurorecovery in traumatic brain injury-associated diffuse axonal injury: a pilot double-blind randomized trial. J Head Trauma Rehabil. 2002;17(4):300-313.
16. Zasler ND. Bromocriptine: neuropharmacology and clinical caveats. J Head Trauma Rehabil. 1995;10(4):101-104.
17. McDowell SK. A role for dopamine in executive function deficits. J Head Trauma Rehabil. 1996;11(6):89-92.
18. Whitlock JA Jr. Brain injury, cognitive impairment, and donepezil. J Head Trauma Rehabil. 1999;14(4):424-427.
19. Blount PJ, Nguyen CD, McDeavitt JT. Clinical use of cholinomimetic agents: a review. J Head Trauma Rehabil. 2002;17(4):314-321.
20. Cummings JL. Alzheimer's disease. N Engl J Med. 2004;351:56-67.
21. Zhang L, Plotkin RC, Wang G, Sandel ME, Lee S. Cholinergic augmentation with donepezil enhances recovery in short-term memory and sustained attention after traumatic brain injury. Arch Phys Med Rehabil. 2004;85:1050-1055.
22. Whyte J, Vaccaro M, Grieb-Neff P, Hart T. Psychostimulant use in the rehabilitation of individuals with traumatic brain injury. J Head Trauma Rehabil. 2002;17:284-299.
23. Whyte J, Hart T, Vaccaro M, et al. Effects of methylphenidate on attention deficits after traumatic brain injury: a multidimensional, randomized, controlled trial. Am J Phys Med Rehabil. 2004;83:401-420.
24. Glenn MB, Wroblewski B. The choice of antidepressants in depressed survivors of traumatic brain injury. J Head Trauma Rehabil. 1989;4(3):85-88.
25. Joseph AB, Wroblewski B. Depression, antidepressants, and traumatic brain injury. J Head Trauma Rehabil. 1995;10(2):90-95.
26. Burke WJ, Gergel I, Bose A. Fixed dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry. 2002;63:331-336.
27. Goldstein BJ, Goodnick PJ. Selective serotonin reuptake inhibitors in the treatment of affective disorders, III: Tolerability, safety, and pharmacoeconomics. J Psychopharmacol. 1998;12(suppl B):S55-S87.
28. Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of data from 3744 depressed patients. J Clin Psychiatry. 1998;59:502-508.
29. Gorman JM, Mirtazapine: a clinical overview. J Clin Psychiatry. 1999;60(suppl 17):9-13.
30. Quitkin FM, Taylor BP, Kremer C. Does mirtazapine have a more rapid onset than SSRIs? J Clin Psychiatry. 2001;62:358-361.
31. Serzone® prescribing information. Bristol-Myers Squibb; 2002.
32. Antidepressants. In: McEvoy K, ed. AHFS Drug Information. Bethesda, Md: American Society of Health-System Pharmacists; 2003:2154-2251.
33. Wellbutrin® prescribing information. Glaxo Smith-Kline; 2002.
34. Cassidy JW. Insomnia. J Head Trauma Rehabil. 1991;6(4):81-83.
35. Glenn MB. Zolpidem for the treatment of insomnia. J Head Trauma Rehabil. 1996;11(2):96-98.
36. Thaxton L, Myers MA. Sleep disturbances and their management in patients with brain injury. J Head Trauma Rehabil. 2002;17(4):335-348.
37. Cardenas DD. Antipsychotics and their use after traumatic brain injury. J Head Trauma Rehabil. 1987;2(4):43-49.
38. Elovic EP. Atypical antipsychotics: risperidone and clozzpine. J Head Trauma Rehabil. 1996;11(3):89-92.
39. Elovic EP, Lansang R, Li Y, Ricker JH. The use of atypical antipsychotics in traumatic brain injury. J Head Trauma Rehabil. 2003;18:177-195.
40. Cassidy JW. Neuropharmacologic management of destructive behavior after traumatic brain injury. J Head Trauma Rehabil. 1994;9(3):43-60.
41. DeDeyn PP, Rabberu K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology. 1999;53:946-955.
42. Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized double-blind trial. J Clin Pychiatry. 1999;60:107-115.
43. Mintzer JE, Faison W, Street JS, et al. Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease. A post-hoc analysis. Int J Geriatr Psychiatry. 2001;16(suppl 1):S71-S77.
44. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer's disease in nursing care facilities: a double-blind randomized placebo-controlled trial. The HGEU study group. Arch Gen Psychiatry. 2000;57(10):968-976.
45. Tariot PN, Salzman C, Yeung PP, et al. Long term use of quetiapine in elderly patients with psychotic disorders. Clin Ther. 2000;22(9):1068-1084.
46. Ziprasidone® (Geodon) prescribing information. Pfizer-Roerig; 2001.
47. Pigott TA, Carion WH, Saha AR, et al. Aripiprazole for prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26 week study. J Clin Psychopharmacol. 2003;64:1048-1056.
48. Casey D, Haupt D, Newcomer J, et al. Antipsychotic induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry. 2004;65(suppl 7):4-16.
49. Risperidone® (Risperdal) prescribing information. Janssen Pharmaceutica; March 2003.
50. Herrmann N, Mamdani M, Lanctot KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry. 2004;161:1113-1115.
51. Kaplan MS. Tizanidine: another tool in the management of spasticity. J Head Trauma Rehabil. 1997;12(5):93-97.
52. Glenn M. Nerve blocks in the treatment of spasticity. J Head Trauma Rehabil. 1986;1(3):72-74.
53. Borg-Stein J, Stein J. Pharmacology of botulinum toxin and implications for use in disorders of muscle tone. J Head Trauma Rehabil. 1993;8(3):103-106.
54. Brashear A, Gorden MF, Elovic E, et al, for the Botox Post-Stroke Spasticity Study Group. Intramuscular injection of botulinum toxin for treatment of wrist and finger spasticity after a stroke. N Engl J Med. 2002;347:395-400.
55. Glenn MB, Elovic E. Chemical denervation for the treatment of hypertonia and related motor disorders: phenol and botulinum toxin. J Head Trauma Rehabil. 1997;12(6):40-62.
56. Brashear A, McAfee AL, Kuhn ER, Fyffe J. Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial. Arch Phys Med Rehabil. 2004;85:705-709.
57. Wallen MA, O'Flaherty SJ, Waugh MA. Functional outcomes of intramuschular botulinum toxin type A in the upper limbs of children with cerebral palsy: a phase II trial. Arch Phys Med Rebabil. 2004;85:192-200.
58. Meythaler JM. Intrathecal baclofen for spastic hypertonia in brain injury. J Head Trauma Rehabil. 1997;12(1):87-90.
59. Coffey RJ, Edgar TS, Francisco GE, et al. Abrupt withdrawal from intrathecal bacofen: recognition and management of a potentially life-threatening syndrome. Arch Phys Med Rehabil. 2002;83:735-741.
60. Banovac K. The effect of etidronate on late development of heterotopic ossification after spinal cord injury. J Spinal Cord Med. 2000;23(1):40-44.
61. Glenn MB. Etidronate disodium: effects on heterotopic ossification and osteoporosis. J Head Trauma Rehabil. 1993;8(3):97-100.
62. Lindenmayer JP, Kotsaftis A. Use of sodium valproate in violent and aggressive behaviors: a critical review. J Clin Psychiatry. 2000;61:123-128.
63. Ikonomidou C, Turski L. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol. 2002;1:383-386.
64. Marshall JWB, Green AR, Ridley RM. Comparison of the neuroprotective effect of clomethiazole, AR-R15896AR and NXY059 in a primate model of stroke using histological and behavioural measures. Brain Res. 2003;972:119-126.
65. Zafonte RD, Elovic E. St. John's won. J Head Trauma Rehabil. 2001;16(5):519-522.
66. Elovic EP, Zafonte RD. Ginkgo biloba: applications in traumatic brain injury. J Head Trauma Rebabil. 2001;16(6):603-607.
67. Solomon PR, Adams F, Silver A, Zimmer J, DeVeaux R. Ginkgo for memory enhancement. A randomized controlled trial. JAMA. 2002;288:835-840.
68. Lexell J. Ginseng. J Head Trauma Rehabil. 2003;18:196-200.